Mono Unsaturated Fatty Acids in Obesity - Weight Maintenance and Prevention of Lifestyle Diseases in Obese Subjects.
|ClinicalTrials.gov Identifier: NCT00274729|
Recruitment Status : Completed
First Posted : January 11, 2006
Last Update Posted : March 25, 2010
|Condition or disease||Intervention/treatment|
|Overweight Obesity||Behavioral: Mono Unsaturated Fatty Acids in Obesity|
The obesity epidemic has raised concerns, because of complications such as type 2 diabetes, cardiovascular disease and certain types of cancer. Much conflict and confusion about the optimal diet for weight control exists among the public.
The current dietary recommendations aim at reducing the total fat in the diet to less than 30% of calories, increasing carbohydrates to 55-60%, and protein from lean meat and dairy products to 15-20%, and to keep the intake of sugar sweetened soft-drinks limited. There is good evidence from meta-analyses of intervention studies that a low fat diet can prevent weight gain in normal weight individuals, induce a small but clinically relevant weight loss in overweight individuals, and also reduce the risk of cardiovascular disease and type 2 diabetes.
However this recommended diet may not be of the optimal composition in preventing the progressive increase in obesity and lifestyle diseases. The traditional dietary recommendation has been challenged by the epidemiologist Walter Willett, Harvard Medical School in Boston. He claims that dietary fat is less important for the development of obesity, and that the fat content of the diet can be 40-45% of the energy providing from mainly mono- and polyunsaturated fatty acids. Based on mainly large-scale observational studies ('Nurses Health Study') he has developed new dietary guidelines, expressed as a new diet pyramid. In contrast to the current guidelines, more plant oils and plant foods, limited animal products, such as meat and dairy products (even lean products), and increased intake of olive oil, nuts, etc., e.g. guidelines closer to the "Mediterranean Diet".
There is circumstantial evidence to support that this moderate fat, MUFA-rich diet will have a beneficial effect on some of the traditional risk factors for cardiovascular disease and type-2 diabetes. However, there is also growing concern that the increased total fat content will lead to weight gain and increased risk of obesity, and secondary to this, type-2 diabetes and cardiovascular disease. This debate has now been taken up by some of the finest scientific journals. To test this hypothesis the largest and longest dietary intervention trial in Denmark is carried out at the Department of Human Nutrition.
The objective is to identify the diet and diet components most effective for protection against weight gain, weight regain and prevention of life-style diseases in obese subjects. The three diets tested are according to:
- Willetts new dietary recommendations. High in mono unsaturated fat and low in glycemic index (50 subjects).
- The traditional dietary recommendations. Low in fat and medium in glycemic index (50 subjects).
- The average Danish diet (Control). High in fat and high in glycemic index (25 subjects).
The diets are ad libitum (i.e. no restriction in calorie intake), but very strict in dietary composition.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||125 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||MUFObes: MonoUnsaturated Fatty Acids in Obesity - a Comparison Between 3 Different Diets in Weight Maintenance and the Prevention of Lifestyle Diseases in Obese Subjects. A Randomised, Long-term Intervention Study.|
|Study Start Date :||January 2004|
|Estimated Study Completion Date :||June 2008|
- Changes in body weight
- Weight loss maintenance efficacy (>5% and >10%)
- Body composition (whole body DEXA-scanning)
- Drop-out rate
- Glucose metabolism (Oral Glucose Tolerance Test)
- Endothelium function (flow-mediated vasodilatation, FMD)
- Changes in:
- Blood lipids
- Blood glucose
- Blood coagulation factors
- Blood pressure
- Appetite & diet palatability
- Appetite regulating hormones (during meal test)
- Visual analogue scale (VAS) (during meal test)
- Energy expenditure (24 hour whole body indirect calorimetry)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00274729
|Principal Investigator:||Arne Astrup, MD DMSC||Department of Human Nutrition, The Royal Veterinary & Agricultural University|